ArticleJournal of vascular surgery. Venous and lymphatic disorders2026
Three-year outcomes after cyanoacrylate closure of superficial truncal veins: A single-center practice cohort study.
Article in Journal of vascular surgery. Venous and lymphatic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of foam sclerotherapy for great saphenous vein reflux: a systematic review and meta-analysis of RCTs.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate mid-term durability, clinical outcomes, and patient-reported outcomes after cyanoacrylate closure (CAC) of superficial truncal veins in routine practice, with limb- and vein-level analyses.
methodsThis was a single-center, retrospective cohort study of adults previously treated with CAC of the great saphenous vein, small saphenous vein, anterior saphenous vein, or posterior accessory saphenous vein, with standardized follow-up assessments. Eligible patients were invited for standardized follow-up including duplex ultrasound, CEAP class, revised Venous Clinical Severity Score, EuroQol 5-dimension survey, and Aberdeen Varicose Vein Questionnaire. The primary endpoint was complete closure of the primary target vein on duplex ultrasound, defined as no ≥5-cm contiguous patency within the treated segment. Secondary endpoints included vein-level patency, new clinically significant varicose veins, adverse events, and satisfaction with symptoms and cosmetic appearance. Analyses accounted for clustering of veins/limbs within patients using generalized estimating equations.
resultsThe study enrolled 89 patients (76.4% female; median age, 53 years) representing 110 limbs and 156 treated veins. The median time from treatment to follow-up was 3.7 years. Primary target vein complete closure at the limb level was 97.3% (107/110; 95% confidence interval [CI], 91.9%-99.1%). At follow-up, patency in any treated vein was present in 10.9% of limbs and 7.7% of veins. At follow-up, revised Venous Clinical Severity Score decreased from 6 (interquartile range, 4-8) to 1 (interquartile range, 0-2) (mean change, -4.5 ± 2.5; P < .001) and Aberdeen Varicose Vein Questionnaire scores improved among the subset with paired data (mean change, -7.7 ± 8.9; P < .001). New clinically significant varicose veins were present in 19.1% of limbs (95% CI, 12.7%-27.8%), often involving the anterior saphenous vein. Higher baseline body mass index was associated with vein-level patency on univariable analysis (median 33 vs 24 kg/m
conclusionsComplete closure rates of all treated veins with CAC remain high at a median of 3.7 years post treatment with sustained clinical and patient-reported outcome improvements. Incomplete closure and recurrent varicose veins correlate with worse symptoms, visual appearance and patient satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.